We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-18.21%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12.2B
AUM Growth
-$2.97B
Cap. Flow
+$24.4M
Cap. Flow %
0.2%
Top 10 Hldgs %
86.1%
Holding
101
New
4
Increased
12
Reduced
21
Closed
10

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$219M
2
AMRN
Amarin Corp
AMRN
+$155M
3
KOD icon
Kodiak Sciences
KOD
+$81M
4
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$22.3M
5
KRYS icon
Krystal Biotech
KRYS
+$14M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$143M
2
SAGE
Sage Therapeutics
SAGE
+$80.2M
3
NVTA
Invitae Corporation
NVTA
+$58.3M
4
ECYT
Endocyte, Inc. Common Stock
ECYT
+$45.3M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$21.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.36%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
26
DELISTED
Cymabay Therapeutics
CBAY
$38.7M 0.32%
4,917,700
– –
TCDA
27
DELISTED
Tricida, Inc. Common Stock
TCDA
$37.7M 0.31%
1,600,000
– –
DBVT
28
DBV Technologies
DBVT
$914M
$35.4M 0.29%
550,956
– –
ZYME icon
29
Zymeworks
ZYME
$2.05B
$25.1M 0.21%
1,708,472
+397,387
+30% +$5.21M
INSM icon
30
Insmed
INSM
$27.5B
$24.3M 0.2%
1,851,982
– –
NGNE icon
31
Neurogene
NGNE
$773M
$23.6M 0.19%
546,708
– –
BOLD
32
DELISTED
Audentes Therapeutics, Inc
BOLD
$19.4M 0.16%
910,463
+517,241
+132% +$13.3M
QURE icon
33
uniQure
QURE
$3.36B
$17.4M 0.14%
605,000
– –
KRYS icon
34
Krystal Biotech
KRYS
$10.3B
$16.3M 0.13%
784,674
+670,000
+584% +$14M
MRUS
35
DELISTED
Merus
MRUS
$16.2M 0.13%
1,160,014
– –
AIMT
36
DELISTED
Aimmune Therapeutics
AIMT
$16.1M 0.13%
673,908
– –
XNCR icon
37
Xencor
XNCR
$2.07B
$15.9M 0.13%
440,186
-162,309
-27% -$5.96M
SLDB icon
38
Solid Biosciences
SLDB
$997M
$15.8M 0.13%
39,192
– –
MYOK
39
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$15.4M 0.13%
315,243
-41,972
-12% -$2.31M
ABEO icon
40
Abeona Therapeutics
ABEO
$348M
$15M 0.12%
84,127
-3,248
-4% -$708K
RARX
41
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$15M 0.12%
823,113
+645,161
+363% +$10.1M
ACGN
42
DELISTED
Aceragen Inc
ACGN
$13.4M 0.11%
284,769
+138
+0% +$15.9K
SYRE icon
43
Spyre Therapeutics
SYRE
$9.39B
$12.8M 0.11%
68,544
+13,029
+23% +$2.76M
SGMO
44
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$11.5M 0.09%
999,823
-284,100
-22% -$3.53M
CFRX
45
DELISTED
ContraFect Corporation
CFRX
$10.9M 0.09%
8,941
– –
NVAX icon
46
Novavax
NVAX
$1.47B
$8.68M 0.07%
235,916
– –
MRKR icon
47
Marker Therapeutics
MRKR
$23.2M
$8.32M 0.07%
+150,000
New +$10.9M
BLCM
48
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$7.82M 0.06%
267,782
– –
ANAB icon
49
AnaptysBio
ANAB
$1.71B
$7.21M 0.06%
113,086
– –
IFRX icon
50
InflaRx
IFRX
$309M
$6.51M 0.05%
178,987
– –
1
2
3 4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2018 Portfolio in Review

As of Q4 2018, Julian Baker held 101 positions worth $12.2B, down 20% from $15.2B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q4 2018 filing shows 4 new, 12 increased, 21 reduced and 10 closed positions. Its largest new stake was Kodiak Sciences: 9,145,115 shares worth $64.9M. The largest sale was Genomic Health, Inc., an estimated $143M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q4 2018 buy was Kodiak Sciences: 9,145,115 shares worth $64.9M.
  • Julian Baker added most to Acadia Pharmaceuticals in Q4 2018, an estimated $219M increase.
  • Julian Baker's biggest Q4 2018 reduction was Genomic Health, Inc., cutting an estimated $143M.
  • Julian Baker fully exited Sage Therapeutics in Q4 2018, selling an estimated $80.2M.
  • Julian Baker's ten largest holdings make up 86% of its $12.2B portfolio in Q4 2018.
  • Julian Baker opened 4 new positions and closed 10 in Q4 2018.
  • Julian Baker's portfolio value fell 20% quarter-over-quarter to $12.2B.

Based on Baker Bros. Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.